| 12/10/04 |
Panacos Pharmaceuticals Announces Initiation of Phase 2 Clinical Development of its HIV Drug Candidate, PA-457 |
| 11/23/04 |
Panacos Pharmaceuticals' HIV Drug Candidate, PA-457, Exhibits Potent Anti-HIV Activity Following a Single Dose in HIV-infected Patients |
| 11/08/04 |
Panacos Pharmaceuticals Amends Merger Agreement with V.I. Technologies |
| 09/15/04 |
Boston Biomedica Announces the Sale of its Diagnostics and Biotech Divisions to SeraCare Life Sciences |
| 07/14/04 |
Panacos Pharmaceuticals Presents Phase 1 Clinical Data on
First-in-Class HIV-1 Maturation Inhibitor, PA-457, at
XV International AIDS Conference, Bangkok, Thailand |
| 06/17/04 |
Panacos Pharmaceuticals to Present Phase 1 Data on Its Lead HIV-1 Drug
Candidate, PA-457, at XV International AIDS Conference, Bangkok, Thailand |
| 06/08/04 |
Boston Biomedica Announces Sale of BBI Source Scientific |
| 06/04/04 |
Panacos Pharmaceuticals Presents Data on HIV Maturation Inhibitor
PA-457 at 13th International Symposium on HIV & Emerging
Infectious Diseases |
| 06/03/04 |
Panacos Pharmaceuticals to Merge With V.I. Technologies |
| 06/01/04 |
Panacos Pharmaceuticals Completes Single Dose Phase 1 Clinical Trial
of PA-457 and Initiates Multiple Dose Study of this First-in-Class
HIV Maturation Inhibitor |
| 05/18/04 |
Panacos Pharmaceuticals Closes $18.3M Series C Financing |
| 05/17/04 |
Boston Biomedica Reports First Quarter 2004 Financial Results |
| 04/20/04 |
Boston Biomedica, Inc. Announces the Appointment Of
Richard T. Schumacher as Chief Executive Officer (CEO) |
| 04/16/04 |
Boston Biomedica Announces Agreement to Sell its Diagnostics and Biotech
Divisions to SeraCare Life Sciences |
| 04/02/04 |
Boston Biomedica Reports Fourth Quarter
and Fiscal Year End 2003 Financial Results |
| 03/18/04 |
Michael N. Avallone Promoted to Chief Financial Officer
of Boston Biomedica, Inc. |
| 03/16/04 |
Panacos Pharmaceuticals Initiates Phase 1 Clinical Trial of PA-457, the First in a New Class of Oral Anti-HIV Compounds |
| 02/11/04 |
Boston Biomedica, Inc. Announces Completion of a
$2.5 Million Revolving Credit and Security Agreement |
| 02/09/04 |
Panacos Pharmaceuticals to Begin Phase 1 Clinical Trial of the First HIV Maturation Inhibitor, PA-457 |
| 02/09/04 |
Boston Biomedica, Inc. Announces Extension Of Consulting Agreement With Richard T. Schumacher |
| 01/14/04 |
Boston Biomedica, Inc. Announces The Appointment Of P. Thomas Vogel To The
Company's Board Of Directors |
| 01/05/04 |
Boston Biomedica, Inc. Announces the Appointment of J. Donald Payne to the
Company's Board Of Directors |
